These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20205269)

  • 41. On corrected score approach for proportional hazards model with covariate measurement error.
    Song X; Huang Y
    Biometrics; 2005 Sep; 61(3):702-14. PubMed ID: 16135021
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of non-ignorable missing and left-censored longitudinal data using a weighted random effects tobit model.
    Sattar A; Weissfeld LA; Molenberghs G
    Stat Med; 2011 Nov; 30(27):3167-80. PubMed ID: 21898524
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Practical and statistical issues in missing data for longitudinal patient-reported outcomes.
    Bell ML; Fairclough DL
    Stat Methods Med Res; 2014 Oct; 23(5):440-59. PubMed ID: 23427225
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simultaneous inference for longitudinal data with detection limits and covariates measured with errors, with application to AIDS studies.
    Wu L
    Stat Med; 2004 Jun; 23(11):1715-31. PubMed ID: 15160404
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Antiretroviral treatment. Present and future of the combinations].
    Gatell-Artigas JM
    Rev Neurol; 1996 Dec; 24(136):1627-31. PubMed ID: 9064189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-response models for the analysis of non-monotone ignorable missing data.
    Robins JM; Gill RD
    Stat Med; 1997 Jan 15-Feb 15; 16(1-3):39-56. PubMed ID: 9004382
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
    AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New trials reach same conclusion: two drugs are better than AZT alone.
    AIDS Alert; 1995 Nov; 10(11):133-6. PubMed ID: 11362921
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Model selection in the weighted generalized estimating equations for longitudinal data with dropout.
    Gosho M
    Biom J; 2016 May; 58(3):570-87. PubMed ID: 26509243
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hierarchical mixture models for longitudinal immunologic data with heterogeneity, non-normality, and missingness.
    Huang Y; Chen J; Yin P
    Stat Methods Med Res; 2017 Feb; 26(1):223-247. PubMed ID: 25038070
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Random effects and latent processes approaches for analyzing binary longitudinal data with missingness: a comparison of approaches using opiate clinical trial data.
    Albert PS; Follmann DA
    Stat Methods Med Res; 2007 Oct; 16(5):417-39. PubMed ID: 17656452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antedependence models for nonstationary categorical longitudinal data with ignorable missingness: likelihood-based inference.
    Xie Y; Zimmerman DL
    Stat Med; 2013 Aug; 32(19):3274-89. PubMed ID: 23436682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Longitudinal data analysis with non-ignorable missing data.
    Tseng CH; Elashoff R; Li N; Li G
    Stat Methods Med Res; 2016 Feb; 25(1):205-20. PubMed ID: 22637472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of combined zidovudine and didanosine therapy in early asymptomatic primary HIV-1 infection.
    Khajotia RR; Feigley CE; Lee E; Gu J
    AIDS; 1998 Jan; 12(2):222-4. PubMed ID: 9468376
    [No Abstract]   [Full Text] [Related]  

  • 55. ACTG 175 and Delta.
    Torres G
    GMHC Treat Issues; 1995 Oct; 9(10):2-3. PubMed ID: 11362915
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Flexible modeling of multiple nonlinear longitudinal trajectories with censored and non-ignorable missing outcomes.
    Lin TI; Wang WL
    Stat Methods Med Res; 2023 Mar; 32(3):593-608. PubMed ID: 36624626
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
    N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Simulation-based study comparing multiple imputation methods for non-monotone missing ordinal data in longitudinal settings.
    Donneau AF; Mauer M; Lambert P; Molenberghs G; Albert A
    J Biopharm Stat; 2015; 25(3):570-601. PubMed ID: 24905056
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Partially linear mixed-effects joint models for skewed and missing longitudinal competing risks outcomes.
    Lu T; Lu M; Wang M; Zhang J; Dong GH; Xu Y
    J Biopharm Stat; 2019; 29(6):971-989. PubMed ID: 29252088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.